India to Russia: Rituximab Export Trade Route
India has recorded 13 verified shipments of Rituximab exported to Russia, representing a combined trade value of $9.0M USD. This corridor is served by 4 active Indian exporters, with an average shipment value of $694.1K USD. The leading Indian exporter is DR.REDDY'S LABORATORIES LTD, which accounts for 49% of total export value with 6 shipments worth $4.4M USD. On the buying side, JSC R-PHARM is the largest importer in Russia with $4.4M USD in purchases. The top 3 suppliers — DR.REDDY'S LABORATORIES LTD, DR REDDYS LABORATORIES LIMITED, DR.REDDY'S LABORATORIES LTD — together control 100% of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to Russia Rituximab corridor is one of India's established pharmaceutical export routes, with 13 shipments documented worth a combined $9.0M USD. The route is dominated by DR.REDDY'S LABORATORIES LTD, which alone accounts for roughly 49% of all export value, reflecting the consolidated nature of India's rituximab manufacturing sector.
Across 4 active suppliers, the average shipment value stands at $694.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 83% of all shipments, consistent with rituximab's non-urgent bulk-order profile.
Shipment activity peaks during July–September, with an average transit time of 19 days port-to-port. The route has recorded an annual growth rate of 27.0%, placing it at rank #7 among India's top rituximab export destinations globally.
On the import side, key buyers of Indian rituximab in Russia include JSC R-PHARM, JSC RPHARM, JSC R-PHARM and 1 others. JSC R-PHARM is the single largest importer with 8 shipments valued at $4.4M USD.
Route Characteristics
- Average transit19 days
- Peak seasonQ3
- Primary modeSea freight
- Top portHYDERABAD ACC (INHYD4)
Market Position
- Global rank#7
- Annual growth+27.0%
- Demand growth+24.5%
- Regulatory ease87/100
Top 10 Indian Rituximab Exporters to Russia
Showing top 10 of 4 Indian suppliers exporting Rituximab to Russia, ranked by total trade value (USD)
| Rank | Supplier (Indian Exporter) | Shipments | Total Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | DR.REDDY'S LABORATORIES LTD Avg $730.8K per shipment | 6 | $4.4M | 48.6% |
| 2 | DR REDDYS LABORATORIES LIMITED Avg $803.5K per shipment | 3 | $2.4M | 26.7% |
| 3 | DR.REDDY'S LABORATORIES LTD Avg $742.8K per shipment | 3 | $2.2M | 24.7% |
| 4 | DR REDDY S LABORATORIES LTD Avg $32 per shipment | 1 | $32 | 0.0% |
This table shows the top 10 of 4 Indian companies exporting rituximab to Russia, ranked by total trade value. The listed exporters are: DR.REDDY'S LABORATORIES LTD, DR REDDYS LABORATORIES LIMITED, DR.REDDY'S LABORATORIES LTD , DR REDDY S LABORATORIES LTD. DR.REDDY'S LABORATORIES LTD is the dominant supplier with 6 shipments worth $4.4M USD, giving it a 49% market share. The top 3 suppliers together account for 100% of the total trade value on this route.
Top 10 Rituximab Importers in Russia
Showing top 10 of 4 known buyers in Russia receiving Rituximab shipments from India, ranked by import value
On the receiving end of this trade route, the leading importers of Indian rituximab in Russia include JSC R-PHARM, JSC RPHARM, JSC R-PHARM , JSC R PHARM. The largest importer is JSC R-PHARM, accounting for $4.4M USD across 8 shipments — representing 49% of all rituximab imports from India on this route.
| Rank | Importer / Buyer | Shipments | Import Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | JSC R-PHARM | 8 | $4.4M | 48.6% |
| 2 | JSC RPHARM | 1 | $2.4M | 26.7% |
| 3 | JSC R-PHARM | 3 | $2.2M | 24.7% |
| 4 | JSC R PHARM | 1 | $32 | 0.0% |
Top 10 Rituximab Formulations Imported by Russia
Showing top 10 of 12 product formulations shipped on the India to Russia Rituximab route, ranked by trade value
Russia imports a wide range of rituximab formulations from India, spanning tablets, capsules, suspensions, and combination drugs. The top formulation — RITUXIMAB WCBWORKING CELL BANKQTY:09VIALSNET QTY:27 GMS — accounts for $2.4M USD across 1 shipments. There are 12 distinct product descriptions in the dataset, reflecting the variety of dosage forms and strengths imported.
| Rank | Product Formulation | Shipments | Trade Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | RITUXIMAB WCBWORKING CELL BANKQTY:09VIALSNET QTY:27 GMS | 1 | $2.4M | 26.7% |
| 2 | RITUXIMAB WORKING CELL BANK | 2 | $2.2M | 24.7% |
| 3 | RITUXIMAB WCB(WORKING CELL BANK)(QTY:5 VIALS) | 1 | $1.2M | 13.5% |
| 4 | RITUXIMAB SUBSTANCE-FROZEN SOLUTION CONCENTRATION 19.6 MG/ML WITH BUFFER SOLUTION 123,350 L(QTY: 2417.66 GMS) | 1 | $809.8K | 9.0% |
| 5 | RITUXIMAB SUBSTANCE-FROZEN SOLUTION CONCENTRATION 19 MG/ML WITH BUFFER SOLUTION123,355 L(QTY: 2343.745 GMS) | 1 | $800.1K | 8.9% |
| 6 | RITUXIMAB SUBSTANCE-FROZEN SOLUTION CONCENTRATION 20.5 MG/ML WITH BUFFER SOLUTION 116,466 L(QTY: 2387.553 GMS) | 1 | $799.6K | 8.9% |
| 7 | RITUXIMAB WCB(WORKING CELL BANK)(QTY:3 VIALS) | 1 | $752.6K | 8.3% |
| 8 | RI(RITUXIMAB)LAB CELLS(QTY:1 NOS) | 1 | $1.5K | 0.0% |
| 9 | INTERNAL REFERENCE STANDARDIRSRITUXIMAB0.5ML | 1 | $468 | 0.0% |
| 10 | RITUXIMAB INTERNAL REFERENCE STANDARD | 1 | $76 | 0.0% |
Showing top 10 of 12 Rituximab formulations imported by Russia on this route.
Shipping & Logistics Analysis
Freight mode split and port-of-origin breakdown
Freight Mode Distribution
Sea freight dominates at 83%, typical for bulk pharmaceutical shipments.
Top Ports of Origin
HYDERABAD ACC (INHYD4) handles the highest volume with 6 shipments. Transit time averages 19 days by sea.
Market Dynamics
India's rituximab exports to Russia are driven primarily by a handful of large-scale manufacturers. DR.REDDY'S LABORATORIES LTD with 6 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 4 active exporters signals a competitive but concentrated market — buyers in Russia benefit from supplier diversity while the top tier handles the majority of volume.
The top 3 suppliers — DR.REDDY'S LABORATORIES LTD, DR REDDYS LABORATORIES LIMITED, DR.REDDY'S LABORATORIES LTD — together account for 100% of total trade value on this route. The average shipment value of $694.1K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.
Beyond the primary product category, shipments on this route include closely related formulations such as rituximab working cell bank and rituximab wcb(working cell bank)(qty:5 vials), suggesting that buyers in Russia tend to consolidate orders across related product lines from the same Indian supplier.
On the buying side, JSC R-PHARM is the largest importer with 8 shipments worth $4.4M USD — representing 49% of all rituximab imports from India on this route.
Route Statistics
- Trade Volume
- $9.0M
- Avg. Shipment
- $694.1K
- Suppliers
- 4
- Buyers
- 4
- Transit (Sea)
- ~19 days
- Annual Growth
- +27.0%
Other Rituximab Routes
Unlock the Full India to Russia Rituximab Dataset
TransData Nexus provides verified shipment-level records, supplier contact details, HS code breakdowns, real-time pricing benchmarks, and regulatory compliance guides for 13 shipments on this route.
Frequently Asked Questions — India to Russia Rituximab Trade
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which Indian companies export Rituximab to Russia?
The leading Indian exporters of Rituximab to Russia are DR.REDDY'S LABORATORIES LTD, DR REDDYS LABORATORIES LIMITED, DR.REDDY'S LABORATORIES LTD . DR.REDDY'S LABORATORIES LTD holds the largest market share at approximately 49% of total trade value on this route.
Q What is the total value of Rituximab exports from India to Russia?
India exports Rituximab to Russia worth approximately $9.0M USD across 13 recorded shipments. The average value per shipment is $694.1K USD.
Q Which ports does India use to ship Rituximab to Russia?
The most active port of origin is HYDERABAD ACC (INHYD4) with 6 shipments. Indian exporters primarily use sea freight for this route, with 83% of shipments going by sea and 28% by air.
Q How long does shipping take from India to Russia for Rituximab?
The average transit time for Rituximab shipments from India to Russia is approximately 19 days. Sea freight typically takes longer, while air freight can reduce this significantly for urgent orders. Peak shipping activity is observed during July–September.
Q Is the India to Russia Rituximab trade route growing?
Yes — this trade corridor has seen an annual growth rate of approximately 27.0% with demand growth tracking at 24.5%. The route is ranked #7 among India's top Rituximab export destinations globally.
Q How many suppliers are active on the India to Russia Rituximab route?
There are currently 4 active Indian suppliers exporting Rituximab to Russia. The market is moderately concentrated with DR.REDDY'S LABORATORIES LTD accounting for 49% of total shipment value.
Q Who are the main importers of Rituximab from India in Russia?
The leading importers of Indian Rituximab in Russia include JSC R-PHARM, JSC RPHARM, JSC R-PHARM , JSC R PHARM. JSC R-PHARM is the largest buyer with 8 shipments worth $4.4M USD.
Official References & Regulatory Resources
- India Trade Statistics (DGFT)
- Invest India — Pharma Sector
- WCO HS Nomenclature
- Ministry of Commerce — Pharma Exports
- Pharmexcil
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Route Identification: India to Russia export trade corridor identified from Indian Customs (DGFT) records for Rituximab.
- 2.Supplier/Buyer Matching: 4 Indian exporters and 4 importers in Russia matched using name normalization.
- 3.Value Aggregation: Total export value aggregated from 13 verified shipping bill records. Values are FOB in USD.
- 4.Market Share Analysis: Each supplier and buyer contribution calculated as a percentage of total route value. Statistical normalization applied to ensure accurate representation across varying shipment sizes.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
13 Verified Shipments
4 Indian exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists